基本情報
- CAS
82248-59-7- 標準SMILES
CNCC[C@@H](Oc1ccccc1C)c1ccccc1.Cl- InChIKey
LUCXVPAZUDVVBT-UNTBIKODSA-N- 分子式
- C17H22ClNO
- 平均分子量
- 291.8 g/mol
- 単同位体質量
- 291.138992
概要
Atomoxetine hydrochloride is the hydrochloride salt of atomoxetine. It has a role as an antidepressant and an adrenergic uptake inhibitor. It contains an atomoxetine.
名称と識別子
- 優先名称
- Atomoxetine Hydrochloride
- IUPAC
- (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine;hydrochloride
- 現地名
- アトモキセチン塩酸塩
- 英語名
- Atomoxetine hydrochloride
- 分子式
- C17H22ClNO
- 分子量
- 291.82
名称と別名
Atomoxetine hydrochloride82248-59-7Atomoxetine HCLTOMOXETINE HYDROCHLORIDE(R)-Tomoxetine hydrochloride(R)-(-)-Tomoxetine hydrochlorideDTXSID2044266LY-139603Atomoxetine (as hydrochloride)57WVB6I2W0(-)-N-Methyl-3-phenyl-3-(o-tolyloxy)propylamine hydrochlorideNSC-759104
名称をさらに表示
アトモキセチン塩酸塩(R)-N-メチル-3-(2-メチルフェノキシ)-3-フェニルプロピルアミン塩酸塩(R)-トモキセチン塩酸塩トモキセチン塩酸塩(R)-トモキセチン 塩酸塩アトモキセチン 塩酸塩アトモキセチン 塩酸塩 溶液アトモキセチン塩酸塩 (JAN)トモキセチン・塩酸塩ストラテラカプセルストラテラ(3R)-N-メチル-3-(2-メチルフェノキシ)-3-フェニル-1-プロパンアミン・塩酸塩アトモキセチン・塩酸塩塩酸アトモキセチンメチル[(R)-3-フェニル-3-(2-メチルフェノキシ)プロピル]アミン・塩酸塩ATOMOXETINEStratteraATOMOXITINEAtomoxetine HCILY 139603LY 139603 HClAtazanavir HCl
物性
構造計算による物性
- 極性表面積
- 21.3 Ų
- 水素結合供与体数
- 2
- 水素結合受容体数
- 2
- 回転可能結合数
- 6
- 重原子数
- 20
- 形式電荷
- 0
- 複雑度
- 237
実験および物理化学的性質
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section162.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 167 · 167-169°C
- 比旋光度
- 25 · D25 -38.01°; 36525 -177.26° (c = 1 in methanol); D23 -41.37° (c = 1.02 in methanol); D25 -40.3° (c = 0.94 in ethanol)
- 闪点
- 9 ℃ · 9℃
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- soluble in Methanol
- 外見
- 個体
- 酸解離定数(Pka)
- 10.13 · 10.13(at 25℃)
- 色
- White to Almost white
- 水溶解度
- 50 mM · Soluble to 50 mM in water with gentle warming
- Merck
- 14 · 14,863
- BCS Class
- 1 · 1
- 主な用途
- 医薬品（低分子化合物）
- InChI
- InChI=1/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/s3
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Danger
H301 (70%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P261, P262, P264, P264+P265, P270, P271, P273, P280, P284, P301+P316, P301+P317, P302+P352, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P318, P319, P320, P321, P330, P337+P317, P361+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 10 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Hazard Classes and CategoriesAcute Tox. 3 (70%)
毒性情報
Treatment
An airway should be established. Monitoring of cardiac and vital signs is recommended, along with appropriate symptomatic and supportive measures. Gastric lavage may be indicated if performed soon after ingestion. Activated charcoal may be useful in limiting absorption. Because atomoxetine is highly protein-bound, dialysis is not likely to be useful in the treatment of overdose. (L1712)
Exposure Routes
Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) have no effect on atomoxetine bioavailability. Absorption is minimally affected by food.
Toxicity Summary
The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined through in-vitro studies. Atomoxetine appears to have minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors.
化学と産業
薬理情報
Metabolism/Metabolites
Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). Half Life: 5 hours
FDA Pharmacological Classification
ATOMOXETINE HYDROCHLORIDE
Norepinephrine Uptake Inhibitors [MoA]; Norepinephrine Reuptake Inhibitor [EPC]
MeSH Pharmacological Classification
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
用途と製造
UsesFor the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.
応用分野
説明Atomoxetine is the first non-stimulant marketed for the treatment of attention deficit hyperactivity disorder (ADHD). It is the R-stereoisomer of the racemate tomoxetine and is a selective and potent norepinephrine uptake inhibitor (Ki=0.7–1.9 nM) that is devoid of binding to monoamine receptor. It also has little effect on dopamine and serotonin reuptake or acetylcholine, H1 histamine, alpha1 or alpha1-adrenergic or dopamine receptors. It is prepared from racemic 1-phenylbut-3-en-1-ol via a selective enzymatic acylation leaving the desired S-stereoisomer as the alcohol. This alcohol is converted via a Mitsunobu reaction with ortho-cresol to the corresponding ether with isomeric R-configuration. Ozonolysis and reduction steps provided the terminal alcohol that is mesylated and displaced with methylamine. Its selectivity for norepinephrine relative to dopamine inhibition was demonstrated in vivo preclinically. In a two-lever (two condition) discriminative stimulus effect study in squirrel monkeys, tomoxetine and other norepinephrine uptake inhibitors substituted for cocaine under low-dose training conditions, whereas dopamine uptake inhibitors substituted for cocaine in both low and high-dose conditions. In clinical ADHD studies in adolescents, it was significantly different from placebo in 1.2 and 1.8 mpk/day dosing. In the clinical study in adults using the CAARS scale a 95 mg/day dose provided greater than 30% improvement in total scores. Atomoxetine is about 63% orally bioavailable, is highly protein bound (98%, primarily to albumin) and has a half-life of about 5.2 h. It is metabolized by CYP2D6 resulting in differential clearance for poor metabolizers (halflife of 19 h with a 10 times higher AUC) relative to extensive metabolizers. The total daily dose for children, adolescents and adults is a maximum of 100 mg/day. Common side effects in children and adults include nausea, decreased appetite, and dizziness. Adults may also have insomnia.
関連反応
10 件
化合物ノート
読み込み中…